Wall Street brokerages expect Urovant Sciences Ltd (NASDAQ:UROV) to post earnings per share of ($0.96) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Urovant Sciences’ earnings, with the highest EPS estimate coming in at ($0.86) and the lowest estimate coming in at ($1.08). The firm is expected to report its next quarterly earnings report on Wednesday, May 22nd.
According to Zacks, analysts expect that Urovant Sciences will report full year earnings of ($3.96) per share for the current financial year, with EPS estimates ranging from ($5.17) to ($2.84). For the next financial year, analysts anticipate that the company will post earnings of ($4.18) per share, with EPS estimates ranging from ($6.42) to ($3.12). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Urovant Sciences.
A number of research firms have weighed in on UROV. Zacks Investment Research lowered Urovant Sciences from a “hold” rating to a “sell” rating in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $28.00 target price on shares of Urovant Sciences in a report on Friday, March 22nd. Finally, SunTrust Banks began coverage on Urovant Sciences in a report on Friday, March 15th. They set a “buy” rating and a $24.00 target price for the company. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Urovant Sciences has an average rating of “Buy” and an average price target of $21.13.
In other news, major shareholder Holdings Ltd. Dexxon bought 11,608 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were purchased at an average cost of $7.10 per share, with a total value of $82,416.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Patrick Machado bought 21,608 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The stock was purchased at an average cost of $7.54 per share, for a total transaction of $162,924.32. The disclosure for this purchase can be found here.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC increased its position in shares of Urovant Sciences by 35.2% in the 4th quarter. Perceptive Advisors LLC now owns 625,359 shares of the company’s stock valued at $3,915,000 after acquiring an additional 162,700 shares during the period. FMR LLC grew its position in Urovant Sciences by 11.1% during the 4th quarter. FMR LLC now owns 1,332,701 shares of the company’s stock worth $8,782,000 after purchasing an additional 132,701 shares during the period. BlackRock Inc. acquired a new stake in Urovant Sciences during the 3rd quarter worth about $4,574,000. Man Group plc acquired a new stake in Urovant Sciences during the 3rd quarter worth about $300,000. Finally, Barclays PLC acquired a new stake in Urovant Sciences during the 4th quarter worth about $37,000. 22.77% of the stock is currently owned by hedge funds and other institutional investors.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Recommended Story: Bollinger Bands
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.